Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (Diluted Average) (2019 - 2025)

Bicycle Therapeutics' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $69.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 19.02% year-over-year to $69.3 million; the TTM value through Dec 2025 reached $69.3 million, up 19.02%, while the annual FY2025 figure was $69.3 million, 19.02% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $69.3 million in Q4 2025 per BCYC's latest filing, roughly flat from $69.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $69.3 million in Q3 2025 to a low of $22.1 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $41.7 million, with a median of $32.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 1.34% in 2023, then skyrocketed 72.75% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $25.1 million in 2021, then increased by 18.35% to $29.7 million in 2022, then grew by 20.0% to $35.6 million in 2023, then soared by 63.54% to $58.2 million in 2024, then grew by 19.02% to $69.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Shares Outstanding (Diluted Average) are $69.3 million (Q4 2025), $69.3 million (Q3 2025), and $69.3 million (Q2 2025).